Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis
E. Radzikowska (Warsaw, Poland), E. Wiatr (Warsaw, Poland), K. Blasinska-Przerwa (Warsaw, Poland), M. Jeskiewicz (Warsaw, Poland), R. Langfort (Warsaw, Poland), B. Maksymiuk (Warsaw, Poland), K. Modrzewska (Warsaw, Poland), I. Bestry (Warsaw, Poland), M. Zaleska (Warsaw, Poland), J. Szopinski (Warsaw, Poland), A. Jerzemska (Bydgoszcz, Poland), M. Ochman (Zabrze, Poland), W. Naumnik (Bialystok, Poland), D. Jastrzebski (Zabrze, Poland), W. Piotrowski (Lódz, Poland), K. Roszkowski-Sliz (Warsaw, Poland)
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Radzikowska (Warsaw, Poland), E. Wiatr (Warsaw, Poland), K. Blasinska-Przerwa (Warsaw, Poland), M. Jeskiewicz (Warsaw, Poland), R. Langfort (Warsaw, Poland), B. Maksymiuk (Warsaw, Poland), K. Modrzewska (Warsaw, Poland), I. Bestry (Warsaw, Poland), M. Zaleska (Warsaw, Poland), J. Szopinski (Warsaw, Poland), A. Jerzemska (Bydgoszcz, Poland), M. Ochman (Zabrze, Poland), W. Naumnik (Bialystok, Poland), D. Jastrzebski (Zabrze, Poland), W. Piotrowski (Lódz, Poland), K. Roszkowski-Sliz (Warsaw, Poland). Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis. 3683
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: